Skip to main content

Telik Plunges After Drug Disappoints

Telcyta fails to meet the preset goals of two separate late-stage clinical studies.
  • Author:
  • Publish date:

Updated from 8:32 a.m. EST

Shares of

Telik

undefined

Scroll to Continue

TheStreet Recommends

were tanking after the company said its experimental cancer drug Telcyta failed to meet the preset goals of two separate late-stage clinical studies.

One trial was a 520-patient study designed to evaluate Telcyta in advanced non-small-cell lung cancer. The drug was compared with gefitinib, and it didn't achieve a statistically significant improvement in overall survival, the primary endpoint.

A trial of the drug in ovarian cancer patients also disappointed, the biopharmaceutical company said. A 440-patient study comparing Telcyta with liposomal doxorubicin or topotecan fell short of its main target of demonstrating a statistically significant improvement in overall survival.

Telik's stock was plunging $11.33, or 70%, to $4.93 early Tuesday.